Telehealth’s Expanding Role in Obesity Care
Obesity has long been recognized as one of the most pressing public health issues in the United States, and today its intersection with telehealth is gaining new significance. With the rise of anti-obesity medications (AOMs), particularly GLP-1 receptor agonists such as semaglutide and tirzepatide, more patients are turning to virtual platforms to access treatment, counseling, and long-term management. GLP-1 receptor agonists work by mimicking the effects of the naturally occurring hormone glucagon-like peptide-1, which helps regulate appetite and blood sugar. By slowing gastric emptying, increasing feelings of fullness, and reducing food intake, these medications have been shown to produce substantial and sustained weight loss in many patients. Meanwhile, new data from FAIR Health’s Monthly Telehealth Regional Tracker, which was featured in a PR Newswire article in mid-September, revealed that obesity re-entered the top five telehealth diagnostic categories nationally in June 2025, after first appearing in the tracker in February of this year.